Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of V503 (Gardasil 9) vs Gardasil in Young Women
NCT00543543Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Primary completion
- Apr 2013
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), vulvar cancer and 2 more (4 arms), sponsored by Merck & Co. Primary endpoints: Combined Incidence of HPV Type 31/33/45/52/58-related Disease, Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18/31/33/45/52/58 and 1 more. Started Sep 2007; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vulvar cancervaginal cancergenital warts
Beyond the preview
Go deeper on NCT00543543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543543.